Resultados globales: 3 registros encontrados en 0.03 segundos.
Artículos, Encontrados 3 registros
Artículos Encontrados 3 registros  
1.
7 p, 242.6 KB Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer : results from two randomized first-line panitumumab studies / Boeckx, N. (Center of Medical Genetics, University of Antwerp and Antwerp University Hospital) ; Koukakis, R. (Biostatistics, Amgen Ltd) ; Op de Beeck, K. (Center of Medical Genetics, University of Antwerp and Antwerp University Hospital) ; Rolfo, C. (Department of Oncology, Antwerp University Hospital, Edegem) ; Van Camp, G. (Center of Medical Genetics, University of Antwerp and Antwerp University Hospital) ; Siena, S. (Dipartimento di Oncologia e Emato-Oncologia, Università degli Studi di Milano) ; Tabernero Caturla, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ; Douillard, J.-Y. (Medical Oncology, Institut de Cancérologie de l'Ouest (ICO) René Gauducheau, Nantes, France) ; André, T. (Department of Medical Oncology, Hôpital Saint Antoine; Sorbonne Universités, UMPC Paris 06 and GERCOR, Paris, France) ; Peeters, M. (Department of Oncology, Antwerp University Hospital, Edegem)
Previous studies have reported the prognostic impact of primary tumor sidedness in metastatic colorectal cancer (mCRC) and its influence on cetuximab efficacy. The present retrospective analysis of two panitumumab trials investigated a possible association between tumor sidedness and treatment efficacy in first-line mCRC patients with RAS wild-type (WT) primary tumors. [...]
2017 - 10.1093/annonc/mdx119
Annals of Oncology, Vol. 28 (april 2017) , p. 1862-1868  
2.
10 p, 1016.0 KB Global cancer control : responding to the growing burden, rising costs and inequalities in access / Prager, Gerald W (Medical University of Vienna) ; Braga, Sofia (Instituto CUF Oncologia) ; Bystricky, Branislav (Faculty Hospital Trencin) ; Qvortrup, Camilla (Odense University Hospital. Department of Oncology) ; Criscitiello, Carmen (Istituto Europeo di Oncologia) ; Esin, Ece (Ankara Oncology Education and Research Hospital) ; Sonke, Gabe S (Netherlands Cancer Institute) ; Argilés Martínez, Guillem (Vall d'Hebron Institut d'Oncologia) ; Frenel, Jean-Sebastian (Institut de Cancerologie de l'Ouest Saint-Herblain) ; Karamouzis, Michalis (National and Kapodistrian University of Athens) ; Strijbos, Michiel (AZ KLINA Hospitals) ; Yazici, Ozan (Ankara Numune Education and Research Hospital) ; Bossi, Paolo (Fondazione IRCCS Istituto Nazionale Tumori Milano) ; Banerjee, Susana (Royal Marsden Hospital NHS Foundation Trust) ; Troiani, Teresa (Università degli Studi della Campania Luigi Vanvitelli) ; Eniu, Alexandru (Cancer Institute "Ion Chiricuta") ; Ciardiello, Fortunato (Università degli Studi della Campania Luigi Vanvitelli) ; Tabernero Caturla, Josep (Universitat Autònoma de Barcelona.Departament de Medicina) ; Zielinski, Christoph C (Medical University Vienna, General Hospital, and Vienna Cancer Center) ; Casali, Paolo G (Istituto Nazionale Tumori) ; Cardoso, Fatima (Champalimaud Clinical Center) ; Douillard, Jean-Yves (European Society for Medical Oncology) ; Jezdic, Svetlana (European Society for Medical Oncology) ; McGregor, Keith (European Society for Medical Oncology) ; Bricalli, Gracemarie (European Society for Medical Oncology) ; Vyas, Malvika (European Society for Medical Oncology) ; Ilbawi, André (Disability, Violence and Injury Prevention (NVI), World Health Organization)
The cancer burden is rising globally, exerting significant strain on populations and health systems at all income levels. In May 2017, world governments made a commitment to further invest in cancer control as a public health priority, passing the World Health Assembly Resolution 70. [...]
2018 - 10.1136/esmoopen-2017-000285
ESMO Open, Vol. 3 (february 2018)  
3.
7 p, 814.0 KB Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma : results from a randomised controlled trial / Siena, Salvatore (Università degli Studi di Milano (Italy)) ; Tabernero Caturla, Josep (Vall d'Hebron Institut d'Oncologia (VHIO)) ; Bodoky, Gyorgy (Szent László Hospital (Hungary)) ; Cunningham, David (Royal Marsden National Health Service Foundation Trust (United Kingdom)) ; Rivera, Fernando (Hospital Universitario Marqués de Valdecilla (Santander)) ; Ruff, Paul (University of the Witwatersrand (South Africa)) ; Canon, Jean Luc (Grand Hôpital de Charleroi. Service d'Oncologie-Hématologie (Belgium)) ; Koukakis, Reija (Amgen Ltd. Department of Biostatistics (United Kingdom)) ; Demonty, Gaston (Amgen GmbH. Medical Development (Suïssa)) ; Hechmati, Guy (Amgen GmbH. Global Health Economics (Suïssa)) ; Douillard, Jean-Yves (Institut de Cancérologie de l'Ouest (France)) ; Universitat Autònoma de Barcelona
Metastatic colorectal cancer is rarely curable. Improving quality of life is therefore a key treatment goal. We report quality of life for patients with RAS wild-type metastatic colorectal cancer in the PRIME study. [...]
2016 - 10.1136/esmoopen-2016-000041
ESMO Open, Vol. 1, Issue 2 (March 2016) , art. e000041  

Vea también: autores con nombres similares
2 Douillard, Jean-Yves
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.